The Semaglutide Report

FDA-approved vs compounded semaglutide: what changes?

Compounded semaglutide is not an FDA-approved generic version of OZEMPIC or WEGOVY. FDA says it does not review compounded drugs for safety, effectiveness or quality before marketing. A prescription and a pharmacy license do not change that approval status.1,2

On this page

Start with the product, then the program

An online weight-management program can include a consultation, prescribing, pharmacy fulfillment and follow-up. Those are services. The medicine supplied through the program has its own identity and regulatory status. A polished program page does not tell you whether the product is FDA-approved unless it says exactly what is prescribed and dispensed.

FDA’s compounding questions and answers state that compounded drugs are not FDA-approved. The agency does not verify their safety, effectiveness or quality before they are marketed. That distinction should be clear before a monthly price is compared with an approved branded product.2

This does not mean a reader can diagnose the quality of an individual prescription from a sales page. It means an approval claim must be specific. Ask for the product name and form, whether it is compounded and the name of the pharmacy responsible for dispensing it.

Why compounded does not mean generic

FDA explicitly distinguishes compounded drugs from approved generics. A generic follows an FDA approval pathway and must meet the requirements of that pathway. A compounded preparation does not become an approved generic because a seller describes it as an alternative to a brand.2

The distinction also matters when a trial is cited. A published trial tested a defined intervention in a particular group. Its findings cannot automatically establish equivalent outcomes for a different formulation prepared by another party. Ask what evidence supports the actual product you would receive.

“Same active ingredient” can still leave questions open about the finished preparation. FDA separately warns about semaglutide sodium and acetate, which it describes as different active ingredients from the ingredient in approved drugs. Ingredient identity, product approval and clinical suitability each need their own answer.1 Our guide to semaglutide sodium and acetate takes that ingredient question separately.

When FDA says compounding may be appropriate

FDA explains that some patients have medical needs that cannot be met by an approved medication, such as an allergy to a particular ingredient. Its GLP-1 warning says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.2,1

That is a patient-specific medical question. Ask the prescribing clinician what need is being addressed in your case, which approved options were considered and how the proposed preparation addresses the issue. A lower advertised price, by itself, is not an explanation of a patient’s medical need.

Compounding rules and enforcement policies are more detailed than this distinction. This article does not determine whether a particular pharmacy’s current practice meets every legal condition. Do not treat a general explanation of compounding as a blanket statement that every online semaglutide offer is authorized.

What pharmacy oversight tells you

A state-licensed pharmacy and an FDA-registered outsourcing facility are terms about the entity preparing or dispensing medication. Neither phrase means that every drug it prepares is FDA-approved. FDA’s compounding page describes different regulatory requirements for traditional compounding and outsourcing facilities.2

If a provider says “FDA registered,” ask what is registered: the facility, the ingredient supplier or the finished product. Ask for the legal name of the entity and the source of the claim. Registration language should not stand in for a product’s approval status.

Likewise, a laboratory report should be read for what it actually tested. Ask whether it addresses identity, potency, sterility or something else, and which sample it covers. A test result is not automatically evidence for every quality claim a seller attaches to it.

For consumers, the practical goal is accountability. You should know who prescribes, who dispenses and who answers a medication-specific question. If those roles belong to different companies, ask how they communicate when a problem arises.

Read the product description behind a price

Our September comparison identified the advertised medication for BiltRx as compounded semaglutide. Its service review distinguishes the compounded offer from branded WEGOVY. Confirm the product now offered rather than assuming that a semaglutide listing means branded WEGOVY.

That comparison recorded a same-price-at-every-dose statement for Bayan Health without settling whether the product was compounded or branded. Its newer service review describes the product and initial commitment separately. A clear price policy does not answer the separate question of what medicine would be dispensed.

A fairer way to compare the cost

Write down the product category before the price. Then record the billing term, what the fee includes and what happens after an introductory offer. A compounded program, an approved product with insurance and an approved product paid for in cash may involve different care and payment arrangements.

Ask whether follow-up visits, supplies and pharmacy charges are included. Ask what happens if the clinician decides the offered product is unsuitable and whether the initial payment can be refunded. Those are contract and service terms that should be available before enrollment.

Do not let a low starting price answer a question it cannot answer. It does not establish ingredient identity, approval, appropriate prescribing or continuity of care. A useful comparison keeps those points visible rather than compressing everything into a single monthly number.

What a clear answer should contain

A useful provider response names the medicine, its form and whether it is compounded; identifies the prescribing and dispensing parties; explains the patient-specific rationale; and describes how questions are handled after enrollment. It also states the payment terms without implying that a prepaid figure is a month-to-month price.

If a response leaves one of those points unanswered, ask for the missing detail rather than interpreting a trust badge as the answer. A transparent program should make it possible to understand what you are considering.

The right product for an individual is a clinical decision. This page helps separate the questions so that the consultation, the pharmacy information and the price comparison are all talking about the same thing.

Sources

  1. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    U.S. Food and Drug Administration. Content current as of: 10/01/2026.

  2. Compounding and the FDA: Questions and Answers

    U.S. Food and Drug Administration. Content current as of: 09/16/2025.

A reference, not medical advice, and not a substitute for your prescriber or pharmacist. If you think you are having a medical emergency, call your local emergency number.